• This guideline addresses the acute, continuation, and maintenance phases of major depressive disorder through standardized processes of screening, diagnosis, and symptom management. Unipolar depression with psychosis and bipolar depression are not addressed in this guideline.
• The Patient Health Questionnaire PHQ-9 is recommended as a screening tool for depression.
• For patients with emerging, current suicidal intent, contact the Psychiatric Consult Team (order through COE).
• For cases requiring linkage with community mental health centers, contact Netcare, 614-276-CARE.
Screening
The Patient Health Questionnaire PHQ-9 is recommended to screen for major depression. Total number of symptoms ≥ 5
Diagnostic Criteria
Additional unique criteria Impaired functioning *DSM-V: Diagnostic and Statistical Manual of Mental Disorders, 5 th Edition.
Treatment
• Provide active support. o Advice on exercise and self-management.
• Encourage activation of social support networks (family / friends).
• Consider either an antidepressant or psychological therapy for mild to moderate depression and advise the patient to not use alcohol while taking antidepressants. See page 3 for classes of antidepressant medications.
• Consider combination therapy of an antidepressant plus structured psychological intervention for moderate to severe depression.
• Monitor to assess progress and safety.
• Consider referral to mental health agencies or consultation with a psychiatrist as necessary.
Phases of Treatment
• Acute Phase (6-12 weeks):
o Initial phase of treatment with active signs and symptoms. o Treatment targets response and remission.
• Continuation (4-9 months):
o Following remission, treatment continues with a focus on achieving functional improvement.
• Maintenance (years):
o Treatment continues until signs and symptoms have fully remitted and functional recovery has been achieved.
Treatment Strategies
Optimize Existing Treatments 
Review
• Review patient's adherence to treatment plan and dose of medication if taking an antidepressant.
Re-evaluate
• Re-evaluate diagnosis: o Frequently consider continuing factors of depression, substance abuse, and personality issues. o Reconsider alternative causes such as life events or social stress.
Re-assess
• Reassess comorbidities, especially for anxiety, substance abuse, and personality disorders.
• Assess for medical comorbidities. 
Continuation Treatment
• Following an initial response, consider treatment with a focus on stabilizing or achieving further improvement and ultimately remission.
• To improve clinical outcome, combine psychotherapy with pharmacological treatments and, during longer term treatment (>12 weeks), consider enhancement approaches to medication management.
• Schedule planned follow-up with regular monitoring of side-effects and adjustment of treatment dosage as needed.
• If there is no response to antidepressant treatment within the first 2 weeks or if the patient fails to respond adequately within 6 weeks, consider a treatment change.
• After remission it is important to continue medication treatment for at least 6-12 months to prevent relapse.
• If remission is not achieved by 3 months, seek consultation or a second opinion and continue active treatment.
• If an initial episode included psychotic features, then continue treatment for at least 3 years.
Stages of Illness
• Response:
o Significant reduction in clinical signs/ symptoms (e.g., 50% reduction in PHQ-9 scores).
• Remission:
o State of minimal or no signs/ symptoms but lacking full recovery.
• Recovery:
o Stable state of minimal or no signs/ symptoms.
• Relapse:
o The return of signs and symptoms after a patient has experienced a remission. o See "Risk of Relapse" section below.
• Recurrence:
o Emergence of signs/symptoms following recovery.
Risk of Relapse
• Relapse rates are the highest immediately following remission and diminish with time. 
Antidepressant Medications
Evidence reveals that the greater the severity and duration of depression symptoms, the clearer the benefit of antidepressants.
Sub-Threshold Depression and Dysthymia
• Generally, sub-threshold depression should be treated with support, psycho-education and active monitoring.
• If patients have had a history of major depressive episodes or if the symptom duration has lasted longer than 2 years, antidepressant medication may be indicated.
Mild Depression
• Low intensity psychosocial interventions and psychological interventions are indicated.
• If these interventions fail, then antidepressants are recommended.
Moderate Depression
• Antidepressants alone are indicated for moderate depression.
• Antidepressants and evidenced-based psychotherapy (e.g., cognitive behavioral therapy, dialectical behavioral therapy, etc.) may be used together for patients with significant psychosocial problems or co-morbid Axis II disorders.
Severe Depression
• A combination of antidepressant medication and evidenced-based psychotherapy is indicated.
• Electroconvulsive therapy may also be considered first line in severe depression. 746-58, indicated that mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine, fluoxetine, fluvoxamine, and paroxetine. o Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, and venlafaxine.
Typical First Choices

Typical Second Choices
• Typical second choices are tricyclic antidepressants (TCAs), which tend to have more numerous and more severe side -effects; therefore, they are often not prescribed until SSRIs have been tried first without an improvement.
Typical Last Choices
• Typical last choices are monoamine oxidase inhibitors (MAOIs). 
QTc Prolongation
• All classes of antidepressants appear to carry some degree of risk of QT prolongation, with the highest degree of association for QT prolongation noted in clinical studies of citalopram and amitriptyline.
• Antidepressants should be used with caution in patients with risk factors in addition to age and gender for QT prolongation.
• An ECG should be considered at baseline, steady state, at the time of dose increases and if another QT prolonging medicine is added to the treatment regimen.
Drug Interactions of Antidepressants Commonly Used in Primary Care
• 
Side Effects of Antidepressants
• Although all antidepressants can cause unwanted side effects, not everyone experiences the same number or intensity of side effects.
• Side effects often go away or lessen within several weeks of starting an antidepressant.
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